Skip to main content.

Wei Zhang, MD, PhD

Wei Zhang portrait
Assistant Professor, Pathology and Laboratory Medicine

Medical Director of Molecular Pathology in Solid Tumor, Pathology and Laboratory Medicine

wzhang3@kumc.edu

Professional Background

Dr. Wei Zhang received her medical degree from China and her PhD in Japan. She was working as a research associate scientist at Yale University School of Medicine before starting her Pathology residency training. After AP/CP residency training at Mount Sinai St.-Luke’s-Roosevelt Hospital, she completed her GI/Liver Pathology fellowship at Montefiore Medical Center and her Molecular Genetic Pathology fellowship at Mount Sinai Hospital in New York. Before joining The University of Kansas Medical Center, Dr. Zhang has been working as an assistant professor at the University of Wisconsin-Madison before joining KU. She served as the Head of GI and Liver Pathology there.

Education and Training
  • BM, Medicine, China Medical University, Shenyang, Liaoning
  • PhD, Molecular Biology, Ehime University School of Medicine, Toon, Ehime
  • Residency, Pathology (AP/CP), The Mount Sinai Health System, New York, NY
  • Residency, Chief Resident, Pathology (AP/CP), The Mount Sinai Health System, New York, NY
  • Clinical Fellowship, GI/Liver Pathology, The Montefiore Medical Center/Albert Einstein Medical College, Bronx, New York
  • Clinical Fellowship, Molecular Genetic Pathology, The Mount Sinai Health System, New York, NY

Research

Overview

Dr. Zhang is actively engaged in the diagnostic surgical and molecular genetic pathology service and has special clinical interests in solid tumor genetics. Dr. Zhang's major research interests focus on the pathogenesis and treatment of liver, colorectal, and anal cancers. She is also interested in biomarker discovery and development of new molecular diagnostic assays.

Publications
  • Zhang, W, Acuna-Villaorduna, A, Kuan, K, Gupta, S, Hu, S, Ohaegbulam, K, Albanese, J, Kaumaya, M, Levy, R, Hwang, R., R, Zang, X, Lin, J, Liu, Q, Maitra, R, Goel, S. 2021. B7-H3 and PD-L1 Expression Are Prognostic Biomarkers in a Multi-racial Cohort of Patients with Colorectal Cancer.. Clinical colorectal cancer, 20 (2), 161-169. https://pubmed.ncbi.nlm.nih.gov/33745842/
  • Zhang, W, Yao, J, Zhong, M, Zhang, Y, Guo, X, Wang, H., Y. 2021. A Brief Overview and Update on Major Molecular Genomic Alterations in Solid, Bone and Soft Tissue Tumors, and Hematopoietic As Well As Lymphoid Malignancies.. Archives of pathology & laboratory medicine, 145 (11), 1358-1366. https://pubmed.ncbi.nlm.nih.gov/34270703/
  • Gunder, L., C, Moyer, T., H, Johnson, H., R, Auyeung, A., S, Leverson, G., E, Zhang, W, Matkowskyj, K., A, Carchman, E., H. 2023. Anal Cancer Prevention Through the Topical Use of Single or Dual PI3K/mTOR Inhibitors.. The Journal of surgical research, 282, 137-146. https://pubmed.ncbi.nlm.nih.gov/36274448/